X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (27923) 27923
Publication (1276) 1276
Newsletter (455) 455
Book Review (80) 80
Newspaper Article (53) 53
Book Chapter (45) 45
Magazine Article (44) 44
Dissertation (20) 20
Conference Proceeding (10) 10
Transcript (4) 4
Web Resource (3) 3
Reference (2) 2
Trade Publication Article (2) 2
Book / eBook (1) 1
Data Set (1) 1
Government Document (1) 1
Journal / eJournal (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (22744) 22744
female (13703) 13703
male (13641) 13641
vincristine - administration & dosage (11714) 11714
antineoplastic combined chemotherapy protocols - therapeutic use (11664) 11664
middle aged (9285) 9285
adult (8960) 8960
oncology (7557) 7557
cyclophosphamide - administration & dosage (7487) 7487
vincristine - therapeutic use (7289) 7289
vincristine (6992) 6992
aged (6842) 6842
doxorubicin - administration & dosage (6764) 6764
chemotherapy (5464) 5464
prednisone - administration & dosage (5232) 5232
index medicus (5177) 5177
adolescent (4695) 4695
cyclophosphamide - therapeutic use (4302) 4302
child (3951) 3951
hematology (3753) 3753
treatment outcome (3671) 3671
prognosis (3606) 3606
combined modality therapy (3546) 3546
antineoplastic combined chemotherapy protocols - administration & dosage (3534) 3534
prednisone - therapeutic use (3532) 3532
cancer (3361) 3361
doxorubicin - therapeutic use (3216) 3216
animals (3199) 3199
antineoplastic combined chemotherapy protocols - adverse effects (2983) 2983
child, preschool (2972) 2972
vincristine - adverse effects (2964) 2964
methotrexate - administration & dosage (2561) 2561
drug therapy, combination (2519) 2519
vincristine - pharmacology (2493) 2493
remission induction (2241) 2241
cyclophosphamide (2220) 2220
etoposide - administration & dosage (2180) 2180
retrospective studies (2045) 2045
follow-up studies (2034) 2034
doxorubicin (2009) 2009
neoplasm staging (1984) 1984
rituximab (1983) 1983
infant (1964) 1964
lymphoma, non-hodgkin - drug therapy (1875) 1875
lymphoma, large b-cell, diffuse - drug therapy (1873) 1873
bleomycin - administration & dosage (1857) 1857
time factors (1855) 1855
disease-free survival (1818) 1818
antineoplastic agents - therapeutic use (1767) 1767
survival rate (1757) 1757
therapy (1753) 1753
hodgkin disease - drug therapy (1663) 1663
aged, 80 and over (1624) 1624
mice (1584) 1584
lymphomas (1562) 1562
cyclophosphamide - adverse effects (1542) 1542
drug administration schedule (1525) 1525
survival analysis (1512) 1512
procarbazine - administration & dosage (1510) 1510
methotrexate - therapeutic use (1473) 1473
doxorubicin - adverse effects (1428) 1428
pediatrics (1416) 1416
prednisolone - administration & dosage (1412) 1412
survival (1377) 1377
care and treatment (1371) 1371
cisplatin - administration & dosage (1312) 1312
children (1250) 1250
radiotherapy (1246) 1246
prednisone - adverse effects (1235) 1235
cytarabine - administration & dosage (1217) 1217
antineoplastic agents - administration & dosage (1202) 1202
non-hodgkins-lymphoma (1200) 1200
lung neoplasms - drug therapy (1180) 1180
pharmacology & pharmacy (1153) 1153
dose-response relationship, drug (1102) 1102
prednisone (1041) 1041
drug resistance (1038) 1038
antineoplastic combined chemotherapy protocols (1037) 1037
clinical trials as topic (1035) 1035
lymphoma (1021) 1021
young adult (1015) 1015
prospective studies (985) 985
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (968) 968
risk factors (964) 964
dactinomycin - administration & dosage (953) 953
dexamethasone - administration & dosage (944) 944
research (944) 944
antineoplastic agents - pharmacology (943) 943
leukemia (943) 943
tumors (937) 937
lymphoma - drug therapy (935) 935
medicine & public health (935) 935
expression (921) 921
recurrence (911) 911
lymphoma, large b-cell, diffuse - pathology (899) 899
etoposide (881) 881
leukemia, lymphoid - drug therapy (873) 873
medicine, general & internal (862) 862
antibodies, monoclonal, murine-derived (857) 857
vinblastine (844) 844
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (24022) 24022
Japanese (1207) 1207
German (842) 842
French (591) 591
Chinese (476) 476
Spanish (336) 336
Russian (318) 318
Polish (238) 238
Italian (237) 237
Portuguese (38) 38
Dutch (34) 34
Hungarian (31) 31
Danish (23) 23
Hebrew (21) 21
Czech (20) 20
Korean (17) 17
Croatian (13) 13
Serbian (12) 12
Turkish (11) 11
Swedish (10) 10
Norwegian (8) 8
Romanian (8) 8
Ukrainian (7) 7
Bulgarian (5) 5
Finnish (5) 5
Slovak (4) 4
Lithuanian (2) 2
Arabic (1) 1
Bosnian (1) 1
Icelandic (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


BioDrugs, ISSN 1173-8804, 01/2013, Volume 27, Issue 1, p. 69
Journal Article
International Journal of Nanomedicine, ISSN 1176-9114, 04/2015, Volume 10, pp. 3081 - 3095
Journal Article
BLOOD, ISSN 0006-4971, 07/2019, Volume 134, Issue 3, pp. 221 - 222
In this issue of Blood, Ferreri et al report preliminary results from the INGRID trial regarding the feasibility and safety of using engineered tumor necrosis... 
HEMATOLOGY | CYCLOPHOSPHAMIDE | VINCRISTINE | DOXORUBICIN
Journal Article
Biomaterials, ISSN 0142-9612, 2011, Volume 32, Issue 23, pp. 5524 - 5533
Abstract Multifunctional nanoassemblies (MNAs) were successfully developed for controlled delivery of water-soluble cationic vincristine sulfate (VCR) to... 
Advanced Basic Science | Dentistry | P-glycoprotein | Vincristine sulfate | Multifunctional nanoassemblies (MNAs) | Cellular uptake | Pharmacokinetics | Multidrug resistance | SYSTEM | MATERIALS SCIENCE, BIOMATERIALS | ENGINEERING, BIOMEDICAL | RETENTION | DOXORUBICIN | CARRIERS | BREAST-CANCER CELLS | INHIBITION | THERAPY | LOADED NANOPARTICLES | PHOSPHATIDYLSERINE | LIPID HYBRID NANOPARTICLES | Vincristine - pharmacology | Nanoparticles - chemistry | Rats, Wistar | Drug Resistance, Multiple | Humans | ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism | Biological Availability | Drug Resistance, Neoplasm | Male | Polyethylene Glycols - chemistry | Vincristine - metabolism | Tissue Distribution | Lecithins - chemistry | Vincristine - chemistry | Inhibitory Concentration 50 | Vincristine - administration & dosage | Vincristine - pharmacokinetics | Microscopy, Electron, Transmission | Lactic Acid - chemistry | Endocytosis - drug effects | Phosphatidylserines - chemistry | Rats | Static Electricity | Endocytosis - physiology | Particle Size | Animals | Models, Biological | Polyglycolic Acid - chemistry | Cell Line, Tumor | Calorimetry, Differential Scanning | Cell Proliferation - drug effects | Drug Delivery Systems - methods | Phosphatidylethanolamines - chemistry | Transition Temperature | Antimitotic agents | Drug resistance in microorganisms | Clathrin | Biological products | Surface active agents | Sulfates | Antineoplastic agents
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 381, Issue 9873, pp. 1203 - 1210
Summary Background Rituximab plus chemotherapy, most often CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), is the first-line standard of... 
Internal Medicine | SURVIVAL | MAINTENANCE | MEDICINE, GENERAL & INTERNAL | II MULTICENTER | B-CELL | ADVANCED FOLLICULAR LYMPHOMA | CYCLOPHOSPHAMIDE | VINCRISTINE | NON-HODGKINS-LYMPHOMA | COMBINATION | CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Nitrogen Mustard Compounds - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cyclophosphamide - adverse effects | Vincristine - administration & dosage | Adult | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Prednisone - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Treatment Outcome | Nitrogen Mustard Compounds - adverse effects | Disease-Free Survival | Bendamustine Hydrochloride | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - adverse effects | Aged | Infusions, Intravenous | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Usage | Chemotherapy | Bendamustine | Patient outcomes | Lymphomas | Research | Drug therapy | Comparative analysis | Cancer | Antimitotic agents | Care and treatment | Antineoplastic agents | Analysis | Bone marrow | Hematology
Journal Article
Pediatric Blood & Cancer, ISSN 1545-5009, 12/2007, Volume 49, Issue 7, pp. 928 - 940
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 2, pp. 196 - 206
Summary Background Post-transplantation lymphoproliferative disorder (PTLD) develops in 1–10% of transplant recipients and can be Epstein–Barr virus (EBV)... 
Hematology, Oncology and Palliative Medicine | SOLID-ORGAN TRANSPLANTATION | DISTINCT ENTITY | VIRAL LOAD | ONCOLOGY | IMMUNOSUPPRESSION | DISEASE | LYMPHOMA | SINGLE-CENTER | II TRIAL | RECIPIENTS | EPSTEIN-BARR-VIRUS | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prednisolone - administration & dosage | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Organ Transplantation - pathology | Cyclophosphamide - therapeutic use | Epstein-Barr Virus Infections - therapy | Vincristine - administration & dosage | Adult | Female | Herpesvirus 4, Human - pathogenicity | Prednisolone - therapeutic use | France | Lymphoproliferative Disorders - etiology | Doxorubicin - administration & dosage | Antigens, CD20 - immunology | Rituximab | Lymphoproliferative Disorders - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Organ Transplantation - adverse effects | Adolescent | Vincristine - therapeutic use | Epstein-Barr Virus Infections - diagnosis | Lymphoproliferative Disorders - drug therapy | Aged | Germany | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Anthracyclines | Cyclophosphamide | Chemotherapy | Corticosteroids | Organ transplant recipients | Clinical trials | Product development | Epstein-Barr virus | Universities and colleges | Prednisolone | Cancer | Antibodies, Monoclonal, Murine-Derived | Antigens, CD20 | Lymphoproliferative Disorders | Antineoplastic Combined Chemotherapy Protocols | Organ Transplantation | Vincristine | Doxorubicin | Herpesvirus 4, Human | Life Sciences | Immunology | Epstein-Barr Virus Infections
Journal Article
Journal of Pharmaceutical Sciences, ISSN 0022-3549, 07/2011, Volume 100, Issue 7, pp. 2835 - 2848
The purpose of this study is to develop novel stable PEGylated liposome vincristine formulations with optimal antitumor efficacy. Vincristine could interact... 
drug targeting | toxicity | circulation time | drug loading | vincristine | liposomes | pharmacokinetics | complexation | sulfobutyl ether cyclodextrin | efficacy | Complexation | Sulfobutyl ether cyclodextrin | Toxicity | Drug targeting | Efficacy | Drug loading | Liposomes | Circulation time | Pharmacokinetics | Vincristine | CHEMISTRY, MEDICINAL | STERICALLY STABILIZED LIPOSOMES | ENCAPSULATED VINCRISTINE | DOXORUBICIN | PHOSPHOLIPIDS | NEUROTOXICITY | CHEMISTRY, MULTIDISCIPLINARY | STEALTH LIPOSOMES | POLY(ETHYLENE GLYCOL) | INJECTION | PHARMACOLOGY & PHARMACY | MICE | Injections, Intravenous | Models, Chemical | Male | Polyethylene Glycols - chemistry | Drug Carriers | Antineoplastic Agents, Phytogenic - administration & dosage | Vincristine - chemistry | Drug Compounding | Vincristine - administration & dosage | Female | Mice, Inbred DBA | Antineoplastic Agents, Phytogenic - pharmacokinetics | Prostatic Neoplasms - drug therapy | Vincristine - pharmacokinetics | Prostatic Neoplasms - pathology | Drug Stability | Mice, Inbred C57BL | Vincristine - toxicity | Solubility | Antineoplastic Agents, Phytogenic - chemistry | Technology, Pharmaceutical - methods | Chemistry, Pharmaceutical | Antineoplastic Agents, Phytogenic - toxicity | Maximum Tolerated Dose | Animals | beta-Cyclodextrins - chemistry | Analysis of Variance | Tumor Burden - drug effects | Cell Line, Tumor | Vincristine - analogs & derivatives | Mice | Kinetics | Delayed-Action Preparations | Phosphatidylethanolamines - chemistry | Index Medicus
Journal Article
The Oncologist, ISSN 1083-7159, 07/2016, Volume 21, Issue 7, pp. 840 - 847
Journal Article